Evidence map›Paper›PMID 35840060›Full record

ArticleJournal of biomedical informatics2022

KG-Predict: A knowledge graph computational framework for drug repurposing.

Zhenxiang Gao, Pingjian Ding, Rong Xu

Abstract read
In one paragraph

Article in Journal of biomedical informatics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Real-World Data and Causal Machine Learning to Enhance Drug Development.Therapeutic innovation & regulatory science · 2025
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhenxiang GaoCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, 44106 OH, USA. Electronic address: zxg306@case.edu.
Pingjian DingCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, 44106 OH, USA. Electronic address: pxd210@case.edu.
Rong XuCenter for Artificial Intelligence in Drug Discovery, School of Medicine, Case Western Reserve University, Cleveland, 44106 OH, USA. Electronic address: rxx@case.edu.

Funding

Clinical and Translational Science Collaborative of ClevelandUL1TR002548 · NCATS · CASE WESTERN RESERVE UNIVERSITY · PI MCCOMSEY, GRACE A · 2018 to 2022
$35.5M
Greater Southern California Node of the Clinical Trials NetworkUG1DA049435 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YIH-ING HSER · 2019 to 2026
$16.7M
Combine computational prediction, network analysis and genetic screening in C elegans to uncover neurodegenerative causes in Alzheimer's DiseaseR01AG061388 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI CHEN, SHU G., XU, RONG · 2018 to 2022
$3.4M
An Integrated Reverse Engineering Approach Toward Rapid drug Re positioning for Alzheimer's DiseaseR01AG057557 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2017 to 2021
$2.8M
Collision of Alzheimers disease and COVID-19 pandemic in the United States: risks, outcomes, disparities and treatmentsRF1AG076649 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2022 to 2022
$2.3M
Repositioning of Clinically Approved Drugs toward the Prevention and Risk Evaluation of Early Cataract ProgressionR01EY029297 · NEI · CASE WESTERN RESERVE UNIVERSITY · PI MONNIER, VINCENT M, XU, RONG · 2019 to 2021
$2.0M
Construct large-scale phenomes of disease and drugs and develop data-driven systems approaches to understand genetic links between Alzheimer's disease and Neuropsychiatric symptomsR56AG062272 · NIA · CASE WESTERN RESERVE UNIVERSITY · PI XU, RONG · 2018 to 2019
$1.6M
Characterize multifaceted interactions between COVID-19 and alcohol use disorder based on real-time analysis of electronic health records of 62 million adult patientsR01AA029831 · NIAAA · CASE WESTERN RESERVE UNIVERSITY · PI DAVIS, PAMELA B, XU, RONG · 2021 to 2023
$1.1M
NCATS NIH HHS UL1 TR002548NEI NIH HHS R01 EY029297NIAAA NIH HHS R01 AA029831NIA NIH HHS R01 AG057557NIA NIH HHS R01 AG061388NIA NIH HHS R56 AG062272NIA NIH HHS RF1 AG076649NIDA NIH HHS UG1 DA049435
6 · The paper itself

Abstract

The emergence of large-scale phenotypic, genetic, and other multi-model biochemical data has offered unprecedented opportunities for drug discovery including drug repurposing. Various knowledge graph-based methods have been developed to integrate and analyze complex and heterogeneous data sources to find new therapeutic applications for existing drugs. However, existing methods have limitations in modeling and capturing context-sensitive inter-relationships among tens of thousands of biomedical entities. In this paper, we developed KG-Predict: a knowledge graph computational framework for drug repurposing. We first integrated multiple types of entities and relations from various genotypic and phenotypic databases to construct a knowledge graph termed GP-KG. GP-KG was composed of 1,246,726 associations between 61,146 entities. KG-Predict then aggregated the heterogeneous topological and semantic information from GP-KG to learn low-dimensional representations of entities and relations, and further utilized these representations to infer new drug-disease interactions. In cross-validation experiments, KG-Predict achieved high performances [AUROC (the area under receiver operating characteristic) = 0.981, AUPR (the area under precision-recall) = 0.409 and MRR (the mean reciprocal rank) = 0.261], outperforming other state-of-art graph embedding methods. We applied KG-Predict in identifying novel repositioned candidate drugs for Alzheimer's disease (AD) and showed that KG-Predict prioritized both FDA-approved and active clinical trial anti-AD drugs among the top (AUROC = 0.868 and AUPR = 0.364).

Indexed as

Drug RepositioningPattern Recognition, AutomatedKnowledgeKnowledge BasesSemanticsAlzheimer’s diseaseComputational prediction frameworkDrug repurposingKnowledge graph

Identifiers

PMID35840060
PMCPMC9595135

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.